<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">nefr</journal-id><journal-title-group><journal-title xml:lang="ru">Нефрология</journal-title><trans-title-group xml:lang="en"><trans-title>Nephrology (Saint-Petersburg)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1561-6274</issn><issn pub-type="epub">2541-9439</issn><publisher><publisher-name>Pavlov First Saint-Petersburg State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.36485/1561-6274-2026-30-2-54-65</article-id><article-id custom-type="edn" pub-id-type="custom">HUUWJM</article-id><article-id custom-type="elpub" pub-id-type="custom">nefr-2574</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ. КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES. CLINICAL INVESTIGATIONS</subject></subj-group></article-categories><title-group><article-title>Послеоперационный профиль МКН-ХБП и выживаемость после паратиреоидэктомии у пациентов на диализе: ретроспективное когортное одноцентровое исследование</article-title><trans-title-group xml:lang="en"><trans-title>Postoperative CKD-MBD profi le and survival after parathyroidectomy in dialysis patients: a retrospective single-centre cohort study</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3625-1824</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Паршина</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Parshina</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p> Паршина Екатерина Викторовна, ассистент, канд. мед. наук, Клиника высоких медицинских технологий, зав. отделением диализа; ассистент кафедры пропедевтики внутренних болезней</p><p>190020, Санкт-Петербург, наб. р. Фонтанки, д. 154 </p></bio><bio xml:lang="en"><p>Assistant Parshina Ekaterina Viktorovna MD, PhD,  Clinic of High Medical Technologies</p><p>154 Fontanka River Embankment, Saint Petersburg, 190020</p></bio><email xlink:type="simple">e.parshina@spbu.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4483-6654</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Толкач</surname><given-names>А. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Tolkach</surname><given-names>A. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Толкач Алексей Дмитриевич, Клиника высоких медицинских технологий, нефролог отделения диализа</p><p>190020, Санкт-Петербург, наб. р. Фонтанки, д. 154 </p></bio><bio xml:lang="en"><p>Tolkach Alexey Dmitrievich, Clinic of High Medical Technologies, nephrologist of the Dialysis Department</p><p>154 Fontanka River Embankment, Saint Petersburg, 190020</p></bio><email xlink:type="simple">ab2769@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9235-3484</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Земченков</surname><given-names>А. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Zemchenkov</surname><given-names>A. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Земченков Александр Юрьевич, доц., канд. мед. наук, Отделение диализа Городского нефрологического центра </p><p>191104, Санкт-Петербург, Литейный пр., д. 56</p></bio><bio xml:lang="en"><p>Associate Professor Zemchenkov Alexander Yuryevich MD, PhD, nephrologist of dialysis department  </p><p>191104, Liteiny pr.,56 Saint Petersburg nephrologist of dialysis department of the City Nephrology Center of City Mariinsky Hospital</p></bio><email xlink:type="simple">kletk@inbox.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0675-2188</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Новокшонов</surname><given-names>К. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Novokshonov</surname><given-names>K. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Новокшонов Константин Юрьевич, доц., канд. мед. наук, доцент кафедры эндокринной хирургии</p><p>190020, Санкт-Петербург, наб. р. Фонтанки, д. 154</p></bio><bio xml:lang="en"><p>Novokshonov Konstantin Yuryevich, MD, PhD, Associate Professor of the Department of Endocrine Surgery</p><p>154 Fontanka River Embankment, Saint Petersburg, 190020</p></bio><email xlink:type="simple">foretex@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3001-664X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Черников</surname><given-names>Р. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Chernikov</surname><given-names>R. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Черников Роман Анатольевич, проф., д-р мед. наук, кафедра эндокринной хирургии</p><p>190020, Санкт-Петербург, наб. р. Фонтанки, д. 154</p></bio><bio xml:lang="en"><p>Professor Chernikov Roman Anatolievich, MD, PhD, DMedSci, Associate Professor of the Department of Endocrine Surgery</p><p>154 Fontanka River Embankment, Saint Petersburg, 190020</p></bio><email xlink:type="simple">yaddd@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Санкт-Петербургский государственный университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Saint Petersburg State University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Городская Мариинская больница</institution><country>Россия</country></aff><aff xml:lang="en"><institution>City Nephrology Center of City Mariinsky Hospital</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>26</day><month>07</month><year>2026</year></pub-date><volume>30</volume><issue>2</issue><fpage>54</fpage><lpage>65</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Паршина Е.В., Толкач А.Д., Земченков А.Ю., Новокшонов К.Ю., Черников Р.А., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Паршина Е.В., Толкач А.Д., Земченков А.Ю., Новокшонов К.Ю., Черников Р.А.</copyright-holder><copyright-holder xml:lang="en">Parshina E.V., Tolkach A.D., Zemchenkov A.Y., Novokshonov K.Y., Chernikov R.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.nephrolog.ru/jour/article/view/2574">https://journal.nephrolog.ru/jour/article/view/2574</self-uri><abstract><sec><title>ЦЕЛЬ</title><p>ЦЕЛЬ. Оценить связь предоперационных и послеоперационных параметров минеральных и костных нарушений при ХБП (МКН-ХБП) с долгосрочной выживаемостью после паратиреоидэктомии (ПТЭ) у пациентов на диализе. </p></sec><sec><title>ПАЦИЕНТЫ И МЕТОДЫ</title><p>ПАЦИЕНТЫ И МЕТОДЫ. Проведено ретроспективное одноцентровое когортное исследование пациентов на заместительной почечной терапии, перенесших субтотальную или тотальную ПТЭ с аутотрансплантацией в 2011–2019 гг. В анализ включены 485 взрослых пациентов, для которых были доступны предоперационные данные. Оценивали уровни паратгормона (ПТГ), фосфатов, кальция и щелочной фосфатазы до ПТЭ и во временных окнах 3–6, 9–12, 24–36 и 48–60 мес после операции. Первичной конечной точкой была общая летальность; успешная трансплантация почки и окончание наблюдения рассматривались как цензурирующие события. Связь показателей МКН-ХБП с выживаемостью анализировали с помощью моделей пропорциональных рисков Кокса с поправкой на демографические и клинико-анамнестические параметры. </p></sec><sec><title>РЕЗУЛЬТАТЫ</title><p>РЕЗУЛЬТАТЫ. Предоперационные уровни ПТГ, фосфатов и кальция не продемонстрировали значимой связи с выживаемостью ни как непрерывные переменные, ни при делении по квартилям. Напротив, послеоперационный статус МКН-ХБП через 3–6 мес был значимо связан с выживаемостью: в сравнении с профилем (ПТГ 150–300 пг/мл, фосфаты 0,81–1,45 ммоль/л, кальций 2,15–2,50 ммоль/л) сочетание низкого ПТГ с высоким уровнем фосфатов сопровождалось повышением риска смерти. Связи выживаемости с уровнем кальция не выявлено. </p></sec><sec><title>ЗАКЛЮЧЕНИЕ</title><p>ЗАКЛЮЧЕНИЕ. Долгосрочная выживаемость после ПТЭ связана с послеоперационным контролем фосфатов и поддержанием ПТГ в промежуточном диапазоне, тогда как предоперационные параметры МКН-ХБП имеют ограниченное прогностическое значение.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>BACKGROUND</title><p>BACKGROUND. Optimal mineral and bone disorder (CKD-MBD) targets after parathyroidectomy (PTX) in dialysis patients remain undefined, and current guidelines do not address this population specifically. </p></sec><sec><title>PATIENTS AND METHODS </title><p>PATIENTS AND METHODS . This retrospective single-centre cohort study included adult patients on dialysis who underwent subtotal or total PTX with autotransplantation between 2011 and 2019. A total of 485 patients with available preoperative and postoperative laboratory data were analyzed. Serum parathyroid hormone (PTH), phosphate, total and ionized calcium, and alkaline phosphatase were measured before PTX and within predefined postoperative time windows (3–6, 9–12, 24–36 and 48–60 months) to account for intraindividual variability and missing values. The primary endpoint was all-cause mortality; successful kidney transplantation and the end of follow-up were treated as censoring events. Associations between CKD-MBD parameters and survival were examined using Cox proportional hazards models adjusted for demographics, dialysis vintage, primary kidney disease, prior transplantation and type of PTX. </p></sec><sec><title>RESULTS</title><p>RESULTS. Preoperative PTH, phosphate and calcium showed no significant linear or non-linear association with survival, either as continuous variables or across quartiles. In contrast, postoperative CKD-MBD status at 3–6 months provided stronger prognostic discrimination. In comparison with the “intermediate” pattern (PTH 150–300 pg/mL, phosphate 0.81–1.45 mmol/L, calcium 2.15–2.50 mmol/L) combinations of low PTH with high or very high phosphate levels were linked to increased risk. Calcium levels were not consistently associated with survival across time windows or categorizations. </p></sec><sec><title>CONCLUSIONS</title><p>CONCLUSIONS. Long-term survival after PTX in dialysis patients is driven mainly by postoperative phosphate control and maintenance of PTH within an intermediate range, while preoperative CKD-MBD parameters have limited independent prognostic impact.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>минеральные и костные нарушения при ХБП</kwd><kwd>паратиреоидэктомия</kwd><kwd>выживаемость</kwd><kwd>паратгормон</kwd><kwd>фосфатемия</kwd><kwd>кальциемия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>chronic kidney disease–mineral and bone disorder (CKD-MBD)</kwd><kwd>parathyroidectomy</kwd><kwd>survival</kwd><kwd>parathyroid hormone</kwd><kwd>phosphatemia</kwd><kwd>calcemia</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ketteler M, Evenepoel P, Holden RM et al. Chronic kidney disease-mineral and bone disorder: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2025;107(3):405–423. doi:10.1016/j.kint.2024.11.013</mixed-citation><mixed-citation xml:lang="en">Ketteler M, Evenepoel P, Holden RM et al. Chronic kidney disease-mineral and bone disorder: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2025;107(3):405–423. doi:10.1016/j.kint.2024.11.013</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Клинические рекомендации «Хроническая болезнь почек (ХБП)». 2024. Доступно по: https://cr.minzdrav.gov.ru/previewcr/469_3 (дата обращения: 01.02.2026)</mixed-citation><mixed-citation xml:lang="en">Клинические рекомендации «Хроническая болезнь почек (ХБП)». 2024. Доступно по: https://cr.minzdrav.gov.ru/previewcr/469_3 (дата обращения: 01.02.2026)</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Слепцов ИВ, Выборнова НБ, Черников РА и др. Модифицированная интраоперационная методика измерения уровня паратгормона крови при лечении первичного гиперпаратиреоза. Эндокринная хирургия 2015;9(4):12–21</mixed-citation><mixed-citation xml:lang="en">Sleptsov IV, Vybornova NB, Chernikov RA et al. Modified quick parathyroid hormone test in surgery of primary hyperparathyroidism. Endocrine Surgery 2015;9(4):12–21. (In Russ.) doi:10.14341/ serg2015412-21</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Evenepoel P, Jørgensen HS. Parathyroidectomy versus calcimimetic: the lower the PTH the better? J Clin Endocrinol Metab 2022;107(8):e3532–e3533. doi:10.1210/clinem/dgac211</mixed-citation><mixed-citation xml:lang="en">Evenepoel P, Jørgensen HS. Parathyroidectomy versus calcimimetic: the lower the PTH the better? J Clin Endocrinol Metab 2022;107(8):e3532–e3533. doi:10.1210/clinem/dgac211</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Паршина ЕВ, Герасимчук РП, Земченков АЮ. Сравнение исходов коррекции вторичного гиперпаратиреоза паратиреоидэктомией и терапией этелкальцетидом в условиях реальной клинической практики. Нефрология 2025;29(3):67–76</mixed-citation><mixed-citation xml:lang="en">Parshina EV, Gerasimchuk RP, Zemchenkov AYu. Comparison of the outcomes of correction of secondary hyperparathyroidism by parathyroidectomy and etelcalcetide therapy in real clinical practice. Nephrology (Saint-Petersburg) 2025;29(3):67–76. (In Russ.) doi:10.36485/1561-6274-2025-29-3-67-76</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Паршина ЕВ, Толкач АД, Новокшонов КЮ и др. Связь предшествующей терапии цинакальцетом с течением синдрома голодной кости у пациентов, оперированных по поводу вторичного гиперпаратиреоза. Нефрология и диализ 2026;28(2):____</mixed-citation><mixed-citation xml:lang="en">Parshina EV, Tolkach AD, Novokshonov KYu et al. The relationship between previous cinacalcet therapy and the course of hungry bone syndrome in patients who underwent surgery for secondary hyperparathyroidism. Nephrology and Dialysis 2026;28(2):____ (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Новокшонов КЮ, Карелина Ю, Земченков АЮ и др. Результаты скрининга на маркеры минеральных и костных нарушений при хронической болезни почек среди диализных пациентов Северо-Западного федерального округа. Нефрология 2016;20(1):36–50</mixed-citation><mixed-citation xml:lang="en">Novokshonov K, Karelina J, Zemchenkov A et al. Chronic kidney disease mineral and bone disorder markers in screening study among dialysis patients in North-West federal region of Russia. Nephrology (Saint-Petersburg) 2016;20(1):36–50. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Паршина ЕВ, Земченков АЮ, Новокшонов КЮ, Черников РА. Комментарий к статье Д.Д. Долидзе и соавт. «Вторичный гиперпаратиреоз. Специфика, сложности, особенности лечения (обзор литературы). Часть II хирургическое лечение». Нефрология и диализ 2024;26(2):242–245</mixed-citation><mixed-citation xml:lang="en">Parshina EV, Zemchenkov AYu, Novokshonov KYu, Chernikov RA. Comment on the paper by D.D. Dolidze et al.: Secondary hyperparathyroidism. Specific features, complexity, features of treatment (literature review). Part II Surgical treatment. Nephrology and Dialysis 2024;26(2):242–245. (In Russ.) doi:10.28996/2618-98012024-2-242-245</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Вишневский КА, Паршина ЕВ, Земченков АЮ и др. Анализ выживаемости в регистре пациентов на заместительной почечной терапии крупного города (многоцентровое проспективное когортное наблюдательное исследование). Нефрология и диализ 2025;27(1):59–79</mixed-citation><mixed-citation xml:lang="en">Vishnevskii KA, Parshina EV, Zemchenkov AYu et al. Analysis of patients’ survival on renal replacement therapy in a large city: a multicenter prospective cohort observational study. Nephrology and Dialysis 2025;27(1):59–79. (In Russ.) doi:10.28996/2618-98012025-1-59-79</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Fotheringham J, Balasubramanian SP, Harrison B, Wilkie M. Post-parathyroidectomy parathyroid hormone levels: the impact on patient survival in a stage 5 chronic kidney disease population. Nephron Clin Pract 2011;119(2):c113–c120. doi:10.1159/000326683</mixed-citation><mixed-citation xml:lang="en">Fotheringham J, Balasubramanian SP, Harrison B, Wilkie M. Post-parathyroidectomy parathyroid hormone levels: the impact on patient survival in a stage 5 chronic kidney disease population. Nephron Clin Pract 2011;119(2):c113–c120. doi:10.1159/000326683</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Xi QP, Xie XS, Zhang L et al. Impact of different levels of iPTH on all-cause mortality in dialysis patients with secondary hyperparathyroidism after parathyroidectomy. Biomed Res Int 2017;2017:6934706. doi:10.1155/2017/6934706</mixed-citation><mixed-citation xml:lang="en">Xi QP, Xie XS, Zhang L et al. Impact of different levels of iPTH on all-cause mortality in dialysis patients with secondary hyperparathyroidism after parathyroidectomy. Biomed Res Int 2017;2017:6934706. doi:10.1155/2017/6934706</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Luo C, Bian X, Ji C et al. Association between serum intact parathyroid hormone and survival in dialysis patients. Int Urol Nephrol 2025;57(3):1019–1028. doi:10.1007/s11255-024-04288-y</mixed-citation><mixed-citation xml:lang="en">Luo C, Bian X, Ji C et al. Association between serum intact parathyroid hormone and survival in dialysis patients. Int Urol Nephrol 2025;57(3):1019–1028. doi:10.1007/s11255-024-04288-y</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Zhou X, Guo Y, Luo Y. The optimal range of serum intact parathyroid hormone for a lower risk of mortality in incident hemodialysis patients. Ren Fail 2021;43(1):599–605. doi:10.1080/0886022X.2021.1903927</mixed-citation><mixed-citation xml:lang="en">Zhou X, Guo Y, Luo Y. The optimal range of serum intact parathyroid hormone for a lower risk of mortality in incident hemodialysis patients. Ren Fail 2021;43(1):599–605. doi:10.1080/08860 22X.2021.1903927</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Guo W, Zhang H, Zhang Y et al. Low parathyroid hormone versus secondary hyperparathyroidism and survival in patients undergoing hemodialysis: a propensity-matched analysis. Front Endocrinol (Lausanne) 2022;13:869330. doi:10.3389/fendo.2022.869330</mixed-citation><mixed-citation xml:lang="en">Guo W, Zhang H, Zhang Y et al. Low parathyroid hormone versus secondary hyperparathyroidism and survival in patients undergoing hemodialysis: a propensity-matched analysis. Front Endocrinol (Lausanne) 2022;13:869330. doi:10.3389/fendo.2022.869330</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Song Z, Wu C, Wang R et al. The effects of parathyroidectomy vs medical treatments for secondary hyperparathyroidism in patients undergoing dialysis: a meta-analysis. Endocr Pract 2024;30(6):569576. doi:10.1016/j.eprac.2024.04.002</mixed-citation><mixed-citation xml:lang="en">Song Z, Wu C, Wang R et al. The effects of parathyroidectomy vs medical treatments for secondary hyperparathyroidism in patients undergoing dialysis: a meta-analysis. Endocr Pract 2024;30(6):569576. doi:10.1016/j.eprac.2024.04.002</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Song Z, Kasmirski J, Balachandra S et al. Parathyroidectomy is associated with lower mortality and fewer cardiac complications in patients with secondary hyperparathyroidism. Surgery 2026;189:109851. doi:10.1016/j.surg.2025.109851</mixed-citation><mixed-citation xml:lang="en">Song Z, Kasmirski J, Balachandra S et al. Parathyroidectomy is associated with lower mortality and fewer cardiac complications in patients with secondary hyperparathyroidism. Surgery 2026;189:109851. doi:10.1016/j.surg.2025.109851</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Komaba H, Hamano T, Fujii N et al. Parathyroidectomy vs cinacalcet among patients undergoing hemodialysis. J Clin Endocrinol Metab 2022;107(7):2016–2025. doi:10.1210/clinem/dgac142</mixed-citation><mixed-citation xml:lang="en">Komaba H, Hamano T, Fujii N et al. Parathyroidectomy vs cinacalcet among patients undergoing hemodialysis. J Clin Endocrinol Metab 2022;107(7):2016–2025. doi:10.1210/clinem/dgac142</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Yang T, Xue Y, Ren J et al. Analysis of factors influencing cardiovascular events and mortality in patients on dialysis after parathyroidectomy. Curr Pharm Des 2025;31(33):2691–2704. doi: 10.21 74/0113816128390373250507062606</mixed-citation><mixed-citation xml:lang="en">Yang T, Xue Y, Ren J et al. Analysis of factors influencing cardiovascular events and mortality in patients on dialysis after parathyroidectomy. Curr Pharm Des 2025;31(33):2691–2704. doi: 10.21 74/0113816128390373250507062606</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Hernandes FR, Canziani ME, Barreto FC et al. The shift from high to low turnover bone disease after parathyroidectomy is associated with the progression of vascular calcification in hemodialysis patients: a 12?month follow?up study. PLoS One 2017;12(4):e0174811. doi:10.1371/journal.pone.0174811</mixed-citation><mixed-citation xml:lang="en">Hernandes FR, Canziani ME, Barreto FC et al. The shift from high to low turnover bone disease after parathyroidectomy is associated with the progression of vascular calcification in hemodialysis patients: a 12?month follow?up study. PLoS One 2017;12(4):e0174811. doi:10.1371/journal.pone.0174811</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Nascimento Junior CP, Arap SS, Custodio MR et al. Parathyroid hormone levels after parathyroidectomy for secondary hyperparathyroidism. Rev Assoc Med Bras (1992) 2021;67(2):230–234. doi:10.1590/1806-9282.67.02.20200609</mixed-citation><mixed-citation xml:lang="en">Nascimento Junior CP, Arap SS, Custodio MR et al. Parathyroid hormone levels after parathyroidectomy for secondary hyperparathyroidism. Rev Assoc Med Bras (1992) 2021;67(2):230–234. doi:10.1590/1806-9282.67.02.20200609</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Zmijewski PV, Staloff JA, Wozniak MJ, Mazzaglia PJ. Subtotal parathyroidectomy vs total parathyroidectomy with autotransplantation for secondary hyperparathyroidism in dialysis patients: shortand long-term outcomes. J Am Coll Surg 2019;228(6):831–838. doi:10.1016/j.jamcollsurg.2019.01.019</mixed-citation><mixed-citation xml:lang="en">Zmijewski PV, Staloff JA, Wozniak MJ, Mazzaglia PJ. Subtotal parathyroidectomy vs total parathyroidectomy with autotransplantation for secondary hyperparathyroidism in dialysis patients: shortand long-term outcomes. J Am Coll Surg 2019;228(6):831–838. doi:10.1016/j.jamcollsurg.2019.01.019</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Yang L, Zhang NR, Wang HF et al. Evaluation of long-term effects of parathyroidectomy in patients with refractory secondary hyperparathyroidism. Hemodial Int 2025;29(3):354–362. doi:10.1111/ hdi.13222</mixed-citation><mixed-citation xml:lang="en">Yang L, Zhang NR, Wang HF et al. Evaluation of long-term effects of parathyroidectomy in patients with refractory secondary hyperparathyroidism. Hemodial Int 2025;29(3):354–362. doi:10.1111/ hdi.13222</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Yang L, Zhang NR, Wang HF, Chen JN, Yang M, Sun XL, Lv Y, Lu Y, Jia WN, He WW, Zhang L. Evaluation of long-term effects of parathyroidectomy in patients with refractory secondary hyperparathyroidism. Hemodial Int 2025;29(3):354–362. doi:10.1111/hdi.13222. Epub 2025 Apr 4. PMID:40183161</mixed-citation><mixed-citation xml:lang="en">Yang L, Zhang NR, Wang HF, Chen JN, Yang M, Sun XL, Lv Y, Lu Y, Jia WN, He WW, Zhang L. Evaluation of long-term effects of parathyroidectomy in patients with refractory secondary hyperparathyroidism. Hemodial Int 2025;29(3):354–362. doi:10.1111/hdi.13222. Epub 2025 Apr 4. PMID:40183161</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Kuo YC, Wang SY, Hung YL et al. Risk factors of recurrent secondary hyperparathyroidism after adequate primary surgical treatment. Front Endocrinol (Lausanne) 2023;14:1063837. doi:10.3389/ fendo.2023.1063837</mixed-citation><mixed-citation xml:lang="en">Kuo YC, Wang SY, Hung YL et al. Risk factors of recurrent secondary hyperparathyroidism after adequate primary surgical treatment. Front Endocrinol (Lausanne) 2023;14:1063837. doi:10.3389/ fendo.2023.1063837</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Alvarado L, Sharma N, Lerma R et al. Parathyroidectomy versus cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients. World J Surg 2022;46(4):813–819. doi:10.1007/s00268-022-06439-7</mixed-citation><mixed-citation xml:lang="en">Alvarado L, Sharma N, Lerma R et al. Parathyroidectomy versus cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients. World J Surg 2022;46(4):813–819. doi:10.1007/s00268-022-06439-7</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Tartaglione L, Rotondi S, Aucella F et al. Parathyroidectomy and survival in a cohort of Italian dialysis patients: results of a multicenter, observational, prospective study. J Nephrol 2023;36(7):19471955. doi:10.1007/s40620-023-01658-0</mixed-citation><mixed-citation xml:lang="en">Tartaglione L, Rotondi S, Aucella F et al. Parathyroidectomy and survival in a cohort of Italian dialysis patients: results of a multicenter, observational, prospective study. J Nephrol 2023;36(7):19471955. doi:10.1007/s40620-023-01658-0</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Koimtzis G, Stefanopoulos L, Geropoulos G et al. Calcimimetics or parathyroidectomy for kidney transplant recipients: is there still a question? A systematic review, meta-analysis and trial sequential analysis. Endocrine 2025;88(3):671–681. doi:10.1007/s12020-025-04189-9</mixed-citation><mixed-citation xml:lang="en">Koimtzis G, Stefanopoulos L, Geropoulos G et al. Calcimimetics or parathyroidectomy for kidney transplant recipients: is there still a question? A systematic review, meta-analysis and trial sequential analysis. Endocrine 2025;88(3):671–681. doi:10.1007/ s12020-025-04189-9</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
